Benitec Biopharma

$2.59
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.32 (-11.00%) As of 6:59 PM UTC today

Why Robinhood?

You can buy or sell BNTC and other stocks, options, and ETFs commission-free!

About BNTC

Benitec Biopharma Inc. Common Stock, also called Benitec Biopharma, is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA. The listed name for BNTC is Benitec Biopharma Inc. Common Stock.

CEO
Jerel A. Banks
Employees
—
Headquarters
Hayward, California
Founded
2020
Market Cap
11.81M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
546.07K
High Today
$3.02
Low Today
$2.54
Open Price
$2.93
Volume
353.41K
52 Week High
$17.39
52 Week Low
$2.52

BNTC Earnings

-$2.45
-$1.63
-$0.82
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
— per share
Actual
Expected Jun 22, Pre-Market

You May Also Like

TRXC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure